The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Azacitidine EVER Pharma 25 mg/ml powder for suspension for injection

EVER Valinject GmbH PA1774/003/001

Main Information

Trade NameAzacitidine EVER Pharma 25 mg/ml powder for suspension for injection
Active SubstancesAzacitidine
Dosage FormPowder for suspension for injection
Licence HolderEVER Valinject GmbH
Licence NumberPA1774/003/001

Group Information

ATC CodeL01BC07 azacitidine


License statusAuthorised
Licence Issued25/06/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back